* Minimal intervention. Site of application should be covered for the first day after treatment to prevent direct contact with residual or leaking product.
* Complete response was defined as complete removal of the tumour.Eisenhauer EA, et al. European Journal of Cancer 2009;45(2):228–47.
** Results from pivotal field efficacy study: 68/78 dogs achieved a complete response at 28 days after one or two treatments of STELFONTA®.
74 dogs were available for assessment at 12 months following initial complete response to STELFONTA®. 65 dogs (88%) had no evidence of local MCT recurrence
* At the site of STELFONTA® treatment.
Acute inflammatory response with swelling and erythema to the tumour margins and immediate surrounding tissueMelo SR, et al. Veterinary Cancer Society, Houston, Texas, USA.
Necrotic destruction is seen – in dogs this means blackening, shrinkage and leakage of thick discharge
56.5% wounds fully healed
76.5% wounds fully healed
96.5% wounds fully healed
Minimal intervention after treatment:
* Minimal intervention. Site of application should be covered for the first day after treatment to prevent direct contact with residual or leaking product.
“… By following the treatment process to the letter, Daisy coped exceptionally well, and it’s now 18 months later with no recurrence, and her quality of life is excellent. Daisy is now 10 and enjoying her later years with typical Jack Russell zest, energy and appetite!”
Brigitte and Brian Wright
Owners of Daisy
STELFONTA® was discovered by Australian company QBiotics, who found a new biologically active chemical (tigilanol tiglate) in the seed of the Australian native blushwood plant (Fontainea picrosperma).
STELFONTA® is an EMA-approved prescription treatment indicated for:
Tumours must be less than or equal to 8 cm3 in volume, and must be accessible to intratumoural injection.
Important safety information
Formation of wounds is an intended reaction to treatment with STELFONTA®.
Most common adverse events such as pain, injection site bruising, erythema, oedema, lameness in a treated limb and wound formation are related to STELFONTA's mode of action
For more information, please review the Summary Product Characteristics.